natgillin/translations-raw huggingface dataset:
When applied to the eye, phenylephrine makes the muscle of the iris contract (tighten) and allows the pupil to widen.
Kada se primjenjuje na oko, fenilefrin uzrokuje kontrakciju mišića šarenice (stezanje) i omogućuje širenje zjenice.
What benefits of Omidria have been shown in studies?
Koje su koristi lijeka Omidria utvrđene u ispitivanjima?
For the full list of all side effects reported with Omidria, see the package leaflet.
Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Omidria potražite u uputi o lijeku.
How is Omidria used?
Kako se Omidria koristi?
Omidria contains the active substances phenylephrine and ketorolac.
Omidria sadrži djelatne tvari fenilefrin i ketorolak.
What AZILECT is and what it is used for
Što je AZILECT i za što se koristi
AZILECT may be taken with or without food.
AZILECT se može uzeti sa ili bez hrane.
Smoking could decrease the amount of AZILECT in the blood.
Pušenje može smanjiti količinu AZILECT-a u krvi.
Do not stop taking AZILECT without first talking to your doctor.
Nemojte prestati uzimati AZILECT prije razgovora sa svojim liječnikom.
If you take more AZILECT than you should
Ako uzmete više AZILECT-a nego što ste trebali
You should avoid taking AZILECT if you are pregnant, as the effects of AZILECT on pregnancy and the unborn child are not known.
Trebali biste izbjegavati uzimanje AZILECT-a ako ste trudni, jer nije poznato kako AZILECT utječe na trudnoću i nerođeno dijete.
What AZILECT looks like and contents of the pack
Kako AZILECT izgleda i sadržaj pakiranja
MAO Inhibitors
MAO inhibitori
Contents of the pack and other information What AZILECT contains
Sadržaj pakiranja i druge informacije Što AZILECT sadrži
Take the AZILECT carton/ blister or bottle with you to show the doctor or pharmacist.
Ponesite sa sobom AZILECT kutiju/blister ili bočicu da pokažete svom liječniku ili ljekarniku.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove .
Parkinson's disease is associated with symptoms of hallucinations and confusion.
Halucinacije Parkinsonova bolest se povezuje sa simptomima halucinacija i konfuzije.
AZILECT helps to increase and sustain levels of dopamine in the brain.
AZILECT pomaže u povećavanju i održavanju razina dopamina u mozgu.
Other medicines and AZILECT
Drugi lijekovi i AZILECT
This might be enhanced if you take other medicines to treat the symptoms of your Parkinson's disease, or if you take medicines which can make you feel drowsy, or if you drink alcohol while taking AZILECT.
To se može pojačati ako uzimate druge lijekove za liječenje simptoma Parkinsonove bolesti ili ako uzimate lijekove koji Vas mogu omamiti ili pijete alkohol dok uzimate AZILECT.
Tablet 30 tablets
Tableta 30 tableta
- If you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6).
- ako ste alergični na razagilin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6)..
The safety and efficacy of AZILECT in children and adolescents have not been established.
Sigurnost i djelotvornost lijeka AZILECT u djece i adolescenata nisu ustanovljene.
What you need to know before you take AZILECT Do not take AZILECT
Što morate znati prije nego počnete uzimati AZILECT
7 tablets 10 tablets 28 tablets 30 tablets 100 tablets 112 tablets
7 tableta 10 tableta 28 tableta 30 tableta 100 tableta 112 tableta
Non-clinical data reveal no special hazard for humans based on the standard studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, reproduction and development.
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala,
Tell your doctor if you or your family/carer notices that you are developing unusual behaviours where you cannot resist the impulse, urges or cravings to carry out certain harmful or detrimental activities to yourself or others.
Obavijestite Vašeg liječnika ako Vi ili Vaša obitelj/skrbnik primijetite da razvijate neuobičajeno ponašanje u smislu da se ne možete oduprijeti nagonu, potrebi ili žudnji za obavljanjem određenih aktivnosti, škodljivih ili loših za Vas ili druge.
Elderly No change in dose is required for elderly patients (see section 5.2).
Nije potrebna promjena doze kod starijih bolesnika (vidjeti dio 5.2).
The recommended dose of AZILECT is 1 tablet of 1 mg taken by mouth once daily.
Preporučena doza AZILECT-a je 1 tableta od 1 mg uzeta na usta jedanput dnevno.
21 February 2005
Datum prvog odobrenja: 21. veljače 2005.
There is no relevant use of AZILECT in the paediatric population in the indication Parkinson's disease.
Nema relevantne primjene lijeka AZILECT u pedijatrijskoj populaciji za indikaciju Parkinsonove bolesti.
Aluminium/aluminium blister packs of 7, 10, 28, 30, 100 or 112 tablets.
Blisteri Aluminij/aluminij blister pakiranja od 7, 10, 28, 30, 100 ili 112 tableta.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1-aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan.
Metabolizam razagilina se odvija kroz dva glavna puta: N-dealkilacijom i/ili hidroksilacijom te nastaju: 1-aminoindan, 3-hidroksi-N-propargil-1 aminoindan i 3-hidroksi-1 aminoindan.
Symptoms reported following overdose of AZILECT included slightly euphoric mood (light form of mania), extremely high blood pressure and serotonin syndrome (see section 4).
Simptomi zabilježeni nakon predoziranja AZILECT-om uključivali su blago euforično raspoloženje (blagi oblik manije), krajnje visok krvni tlak i serotoninski sindrom (vidjeti dio 4).
Age has little influence on rasagiline pharmacokinetics in the elderly (> 65 years) (see section 4.2)
Starije osobe Dob slabo utječe na farmakokinetiku razagilina u starijih osoba (> 65 godina) (vidjeti dio 4.2).
The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets or in a bottle containing 30 tablets.
Tablete su dostupne u blister pakiranjima od 7, 10, 28, 30, 100 i 112 tableta ili u bočici koja sadrži 30 tableta.
The recommended dose of rasagiline is 1 mg (one tablet of AZILECT) once daily, to be taken with or without levodopa.
Preporučena doza razagilina je 1 mg (jedna tableta lijeka AZILECT) jednom dnevno koja se uzima s levodopom ili bez nje.
If you stop taking AZILECT
Ako prestanete uzimati AZILECT
If you think that you may have taken too many AZILECT tablets, contact your doctor or pharmacist immediately.
Ako mislite da ste možda uzeli previše AZILECT tableta, odmah se obratite svom liječniku ili ljekarniku.
Very common (may affect more than 1 in 10 people) - Involuntary movements (dyskinesia) - Headache
Vrlo često (mogu se javiti u više od 1 na 10 osoba) - nevoljni pokreti (diskinezija) - glavobolja
Levodopa and other Parkinson's disease medicinal products
Levodopa i drugi lijekovi za Parkinsonovu bolest
If you forget to take AZILECT
Ako ste zaboravili uzeti AZILECT
Therefore, AZILECT is not recommended for use under the age of 18.
Stoga se ne preporučuje primjena lijeka AZILECT u djece i adolescenata mlađih od 18 godina.
There is no relevant use of AZILECT in children and adolescents.
Nema relevantne primjene lijeka AZILECT u djece i adolescenata.
AZILECT may cause drowsiness and may cause you to suddenly fall asleep during day time activities, especially if you are taking other dopaminergic medicinal products (used for the treatment of Parkinson's disease).
AZILECT može uzrokovati omamljenost i može učiniti da iznenada zaspite tijekom dnevnih aktivnosti, posebice ako uzimate dopaminergičke lijekove (primjenjuju se za liječenje Parkinsonove bolesti).
Cerebrovascular Serotonin
Cerebrovaskula Serotoninski
If you are starting treatment with fluoxetine or fluvoxamine, you should wait at least 14 days after stopping AZILECT treatment.
Ako započinjete liječenje fluoksetinom ili fluvoksaminom, morate čekati najmanje 14 dana nakon prekida liječenja AZILECT-om.
The use of AZILECT together with the antidepressants containing fluoxetine or fluvoxamine should be avoided.
Istodobnu primjenu AZILECT-a s antidepresivima koji sadrže fluoksetin ili fluvoksamin potrebno je izbjegavati.
AZILECT 1 mg tablets
AZILECT 1 mg tablete
Symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg included hypomania, hypertensive crisis and serotonin syndrome.
Simptomi Simptomi prijavljeni nakon predoziranja razagilinom u dozama u rasponu od 3 mg do 100 mg uključivali su hipomaniju, hipertenzivnu krizu i serotoninski sindrom.
If you are starting treatment with AZILECT, you should wait at least 5 weeks after stopping fluoxetine treatment.
Ako započinjete liječenje AZILECT-om, morate čekati najmanje 5 tjedana nakon prekida liječenja fluoksetinom.
AZILECT is indicated in adults for the treatment of idiopathic Parkinson's disease as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
AZILECT je indiciran u odraslih za liječenje idiopatske Parkinsonove bolesti kao monoterapija (bez levodope) ili kao dodatna terapija (s levodopom) u bolesnika s fluktuacijama prilikom isteka doze.
How to take AZILECT
Kako uzimati AZILECT
Package leaflet: Information for the user AZILECT 1 mg tablets rasagiline
Uputa o lijeku: Informacije za korisnika AZILECT 1 mg tablete razagilin
Non-clinical data indicate that rasagiline inhibits prolactin secretion and thus, may inhibit lactation.
Dojenje Neklinički podaci pokazuju da razagilin inhibira sekreciju prolaktina i prema tome, može inhibirati laktaciju.
Patients with Parkinson's disease are particularly vulnerable to the adverse reactions of hypotension due to existing gait issues.
Parkinsonovom bolesti posebno su osjetljivi na nuspojave hipotenzije zbog postojećih problema s hodanjem.
AZILECT contains the active substance rasagiline and it is used for the treatment of Parkinson's disease in adults.
AZILECT sadrži djelatnu tvar razagilin te se primjenjuje za liječenje Parkinsonove bolesti u odraslih.
In post-marketing period, there was one case of elevated blood pressure in a patient using the ophthalmic vasoconstrictor tetrahydrozoline hydrochloride while taking rasagiline.
U razdoblju nakon stavljanja lijeka u promet bio je jedan slučaj povišenog krvnog tlaka u bolesnika koji je primijenjivao oftalmički vazokonstriktor tetrahidrozolinklorid tijekom uzimanja razagilina.
Adverse reactions are listed below in Tables 1 and 2 by system organ class and frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su navedene u tablicama 1 i 2 prema klasifikaciji organskih sustava i učestalosti prema sljedećem pravilu: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1 000 i < 1/100),
*See section description of selected adverse reactions Adjunct Therapy
*Vidjeti dio s opisom odabranih nuspojava Dodatna terapija
The difference between the mean change from baseline to week 26/termination (LOCF, Last Observation Carried Forward) was statistically significant (UPDRS, parts I-III: for rasagiline 1 mg compared to placebo -4.2, 95% CI [-5.7, -2.7]; p<0.0001; for rasagiline 2 mg compared to placebo -3.6, 95% CI [-5.0, -2.1]; p<0.0001, UPDRS Motor, part II: for rasagiline 1 mg compared to placebo -2.7, 95% CI [-3.87, -1.55], p<0.0001; for rasagiline 2 mg compared to placebo -1.68, 95% CI [-2.85, -0.51], p=0.0050).
Last Observation Carried Forward; posljednje provedeno zapažanje preneseno dalje) je bila statistički značajna (UPDRS, dijelovi I-III: za razagilin 1 mg u usporedbi s placebom -4,2, 95 % CI [-5,7, -2,7]; p< 0,0001; za razagilin 2 mg u usporedbi s placebom -3,6, 95 % CI [-5,0, -2,1]; p< 0,0001, UPDRS motorička, dio II: za razagilin 1 mg u usporedbi s placebom 2,7, 95 % CI [-3,87, -1,55], p< 0,0001; za razagilin 2 mg u usporedbi s placebom -1,68, 95 % CI
Each tablet contains 1 mg of rasagiline (as mesilate).
Svaka tableta sadrži 1 mg razagilina (u obliku mesilata).
Talk to your doctor before taking AZILECT - If you have any liver problems - You should speak with your doctor about any suspicious skin changes.
- morali biste razgovarati sa svojim liječnikom o bilo kakvim sumnjivim promjenama na koži.
In vitro studies showed that rasagiline at a concentration of 1 µg/ml (equivalent to a level that is 160 times the average Cmax ~ 5.9-8.5 ng/ml in Parkinson's disease patients after 1 mg rasagiline multiple dosing), did not inhibit cytochrome P450 isoenzymes, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A.
160 puta veća od prosječne Cmax ~ 5,9-8,5 ng/ml u bolesnika s Parkinsonovom bolešću nakon višekratnog doziranja 1 mg razagilina) nije inhibirao izoenzime citokroma P450, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2El, CYP3A4 i CYP4A.
With MAO inhibitors there have been reports of medicinal product interactions with the concomitant use of sympathomimetic medicinal products.
Simpatomimetici Kod MAO inhibitora su prijavljene interakcije lijekova pri istodobnoj primjeni simpatomimetskih lijekova.
It can be used together with or without Levodopa (another medicine that is used to treat Parkinson's disease).
Može se primjeniti zajedno s levodopom ili bez levodope (drugi lijek koji se primjenjuje za liječenje
Neoplasms benign, malignant and unspecified
Dobroćudne, zloćudne i nespecificirane novotvorine
Your doctor may need to adjust or stop your dose (see section 4).
Vaš liječnik će možda morati prilagoditi dozu ili prekinuti liječenje
If increased somnolence or new episodes of falling asleep during activities of daily living (e.g. watching television, passenger in a car, etc.) are experienced at any time during treatment, the patients should not drive or participate in potentially dangerous activities.
gledanja televizije, vožnje u automobilu kao putnik itd.) bilo kada tijekom liječenja, bolesnik ne smije voziti niti sudjelovati u potencijalno opasnim aktivnostima.
If you have experienced somnolence and/or episodes of sudden sleep onset before, or while taking AZILECT do not drive or operate machinery (see section 2).
Ako ste osjetili izrazitu pospanost i/ili epizode iznenadnog nastupa sna prije ili za vrijeme uzimanja lijeka AZILECT, nemojte upravljati vozilima ili strojevima (pogledajte dio 2).
Serotonin syndrome*, Excessive daytime sleepiness (EDS) and sudden sleep onset (SOS) episodes*
Serotoninski sindrom*, Prekomjerna dnevna pospanost i epizode iznenadnog nastupa sna*
White, high-density polyethylene bottle with or without a child-resistant cap containing 30 tablets.
Bočice Bijele bočice od polietilena visoke gustoće sa ili bez sigurnosnog zatvarača za djecu koje sadržavaju
Ask your doctor for advice before you drive and operate machines, since Parkinson's disease itself as well as the treatment with AZILECT may influence your ability to do so. AZILECT can make you feel dizzy or drowsy; it can also cause episodes of sudden sleep onset.
Upitajte svog liječnika za savjet prije upravljanja vozilima i rada sa strojevima jer Parkinsonova bolest sama po sebi, kao i liječenje lijekom AZILECT, može utjecati na Vašu sposobnost upravljanja vozilima i rada sa strojevima.
There was also a statistically significant improvement over placebo with the rasagiline 0.5 mg group, yet the magnitude of improvement was lower.
0,5 mg skupini u usporedbi s placebom, iako je razmjer poboljšanja bio manji.
In Parkinson's disease patients receiving rasagiline as adjunct therapy to chronic levodopa treatment, there was no clinically significant effect of levodopa treatment on rasagiline clearance.
Kod bolesnika s Parkinsonovom bolešću koji primaju kroničnu terapiju levodopom i razagilin kao dodatnu terapiju nije bilo klinički značajnog učinka terapije levodopom na klirens razagilina.
In patients taking AZILECT and/or other medicines used to treat Parkinson's disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed.
Kod bolesnika koji uzimaju AZILECT i/ili druge lijekove koji se koriste za liječenje Parkinsonove bolesti bila su opažena ponašanja kao što su kompulzije, opsesivne misli, ovisnost o kockanju, prekomjerno trošenje, impulzivno ponašanje i nenormalno visok seksualni nagon ili povećanje misli i osjećanja povezanih sa seksualnošću.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTER PACK
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU KUTIJA ZA BLISTER PAK
Renal impairment No special precautions are required in patients with renal impairment.
Nisu potrebne posebne mjere opreza u bolesnika s oštećenjem bubrega.
AZILECT 1 mg tablets rasagiline
AZILECT 1 mg tablete razagilin
Excessive daytime sleepiness (EDS) and sudden sleep onset (SOS) episodes Rasagiline may cause daytime drowsiness, somnolence, and, occasionally, especially if used with other dopaminergic medicinal products - falling asleep during activities of daily living.
Prekomjerna dnevna pospanost i epizode iznenadnog nastupa sna Razagilin može uzrokovati dnevnu omamljenost, somnolenciju te povremeno, posebice ako se primjenjuje s drugim dopaminergičkim lijekovima, padanje u san tijekom dnevnih aktivnosti.
AZILECT tablets are presented as white to off-white, round, flat, bevelled tablets, debossed with “GIL” and “1” underneath on one side and plain on the other side.
AZILECT tablete su bijele do bjelkaste, okrugle, plosnate tablete kosih rubova, s utisnutom oznakom „GIL” i „1” ispod toga na jednoj strani, i bez oznake na drugoj strani.
- The active substance is rasagiline.
- Djelatna tvar je razagilin.
Co-administration of rasagiline and ciprofloxacin (an inhibitor of CYP1A2) increased the AUC of rasagiline by 83%.
Istodobna primjena razagilina i ciprofloksacina (inhibitora CYP1A2) je povećala AUC razagilina za
In study I, 404 patients were randomly assigned to receive placebo (138 patients), rasagiline 1 mg/day (134 patients) or rasagiline 2 mg/day (132 patients) and were treated for 26 weeks, there was no active comparator.
(138 bolesnika), razagilin 1 mg/dan (134 bolesnika) ili razagilin 2 mg/dan (132 bolesnika) i bili su liječeni 26 tjedana, nije bilo aktivnog komparatora.
In clinical studies in Parkinson's disease patients the most commonly reported adverse reactions were: headache, depression, vertigo, and flu (influenza and rhinitis) in monotherapy; dyskinesia, orthostatic hypotension, fall, abdominal pain, nausea and vomiting, and dry mouth in adjunct to levodopa therapy; musculoskeletal pain, as back and neck pain, and arthralgia in both regimens.
U kliničkim ispitivanjima Parkinsonove bolesti nuspojave koje su bolesnici najčešće prijavljivali bile su: glavobolja, depresija, vrtoglavica i gripa (influenca i rinitis) kod monoterapije; diskinezija, ortostatska hipotenzija, pad, bol u abdomenu, mučnina i povraćanje te suha usta kod dodatne terapije uz levodopu;
In both studies, the primary measure of efficacy was the change from baseline to treatment period in the mean number of hours that were spent in the “OFF” state during the day (determined from “24-hour” home diaries completed for 3 days prior to each of the assessment visits).
„OFF“ stanju tijekom dana (određivano iz „24-satnih“ kućnih dnevnika popunjavanih tijekom 3 dana prije svakog posjeta procjene) od početne vrijednosti do razdoblja liječenja.
There was a significant and beneficial effect in quality of life (as assessed by PD-QUALIF scale).
Učinak na kvalitetu života bio je značajan i koristan
Depression, Hallucinations*
Depresija Halucinacije
Patients and carers should be made aware of the behavioural symptoms of impulse control disorders that were observed in patients treated with rasagiline, including cases of compulsions, obsessive thoughts, pathological gambling, increased libido, hypersexuality, impulsive behaviour and compulsive spending or buying.
Bolesnici i skrbnici moraju biti upoznati sa bihevioralnim simptomima poremećaja kontrole impulsa koji su bili primjećeni kod bolesnika liječenih razagilinom, uključujući slučajeve kompulzija, opsesivnih misli, patološkog kockanja, povećanog libida, hiperseksualnosti,
Rasagiline's pharmacokinetics characteristics in subjects with mild (CLcr 50-80 ml/min) and moderate (CLcr 30-49 ml/min) renal impairment were similar to healthy subjects.
Karakteristike farmakokinetike razagilina u osoba s blagim (CLcr 50-80 ml/min) i umjerenim
Carpal tunnel syndrome, Balance disorder accident syndrome*, Excessive daytime sleepiness (EDS) and sudden sleep onset (SOS) episodes*
Poremećaj ravnoteže rni inzult sindrom*, Prekomjerna dnevna pospanost i epizode iznenadnog nastupa sna*
Results of five tyramine challenge studies (in volunteers and Parkinson's disease patients), together with results of home monitoring of blood pressure after meals (of 464 patients treated with 0.5 or 1 mg/day of rasagiline or placebo as adjunct therapy to levodopa for six months without tyramine restrictions), and the fact that there were no reports of tyramine/rasagiline interaction in clinical studies conducted without tyramine restriction, indicate that rasagiline can be used safely without dietary tyramine restrictions.
1 mg/dan razagilina ili placebom kao dodatnom terapijom levodopi kroz šest mjeseci bez restrikcija tiramina) i činjenicom da nije bilo prijava tiramin/razagilin interakcija u kliničkim ispitivanjima provedenim bez restrikcije tiramina, upućuju na to da se razagilin može primijenjivati sigurno bez dijetalnih restrikcija tiramina.
The tabulated list below includes adverse reactions which were reported with a higher incidence in placebo-controlled studies in patients receiving 1 mg/day rasagiline.
Niže navedeni tablični popis uključuje nuspojave koje su bile prijavljene s većom incidencijom u placebo kontroliranim ispitivanjima u bolesnika koji su primali 1 mg/dan razagilina.
ICDs can occur in patients treated with dopamine agonists and/or dopaminergic treatments.
iznenadni nastup sna) mogu se javiti kod bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim lijekovima.
Incidence of skin melanoma in placebo-controlled clinical studies was 2/380 (0.5%) in rasagiline 1 mg as adjacent to levodopa therapy group vs. 1/388 (0.3%) incidence in placebo group.
(0,5 %) u skupini koja je primala razagilin u dozi od 1 mg kao dodatnu terapiju levodopi naspram incidencije od 1/388 (0,3 %) u skupini koja je primala placebo.
The following were reported during post-marketing exposure with unknown frequency: compulsions, compulsive shopping, dermatillomania, dopamine dysregulation syndrome, impulse-control disorder, impulsive behaviour, kleptomania, theft, obsessive thoughts, obsessive-compulsive disorder, stereotypy, gambling, pathological gambling, libido increased, hypersexuality, psychosexual disorder, sexually inappropriate behaviour.
poremećaj kontrole impulsa, impulzivno ponašanje, kleptomanija, krađa, opsesivne misli, opsesivno kompulzivni poremećaj, stereotipija, kockanje, patološko kockanje, povećani libido, hiperseksualnost, psihoseksualni poremećaj, neprimjereno seksualno ponašanje.
After oral administration of 14C-labelled rasagiline, elimination occurred primarily via urine (62.6%) and secondarily via faeces (21.8%), with a total recovery of 84.4% of the dose over a period of 38 days.
a sekundarno putem fecesa (21,8 %), s potpunim izlučivanjem 84,4 % doze lijeka tijekom razdoblja od
- Any combination of hallucinations, fever, restlessness, tremor and sweating (serotonin syndrome) - If you notice any suspicious skin changes because there is a higher risk of skin cancer (not exclusively melanoma) in patients with Parkinson's disease (see section 2).
- Ako primijetite sumnjive promjene na koži zbog toga jer postoji povećani rizik od raka kože (koji ne mora nužno biti melanom) u bolesnika s Parkinsonovom bolešću (pogledajte dio 2).
Not known: frequency cannot be estimated from the available data - Elevated blood pressure - Excessive drowsiness - Sudden onset of sleep
- povišeni krvni tlak - prekomjerna omamljenost - iznenadni nastup sna
Not known disorders
Nepoznato sustava